Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in Adults With Overweight or Obesity, With or Without Type 2 Diabetes
ClinicalTrials.gov · NCT07944118 · Registry updated: 2026-11-18
- Condition / research focus
- Overweight; Obesity; Type 2 Diabetes
- Sponsor
- Novo Nordisk A/S
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2026-11-12. Completion: 2028-02-11 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Zenagamtide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Altasciences Clinical LA, Inc.
Cypress, California, United States